# Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma

> **NCT05440942** · PHASE1 · COMPLETED · sponsor: **Peter Hosein, MD** · enrollment: 28 (actual)

## Conditions studied

- Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** Trametinib
- **DRUG:** Ruxolitinib
- **DRUG:** Retifanlimab

## Key facts

- **NCT ID:** NCT05440942
- **Lead sponsor:** Peter Hosein, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-19
- **Primary completion:** 2025-05-30
- **Final completion:** 2025-05-30
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2025-06-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05440942

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05440942, "Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05440942. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*